American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...
Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...
Zacks.com on MSN1d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback